China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates
China’s National Cancer Center (NCC) has released the latest national cancer statistics, approved by the...
Johnson & Johnson’s Kenvue Partners with Tencent for Integrated Health Services in China
Johnson & Johnson (J&J, NYSE: JNJ)’s consumer health spinoff Kenvue and its Chinese partner Tencent...
Chongqing Genrix Biopharmaceutical Gets NMPA Clearance for IL-4Rα mAb Candidate GR1802
Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a Chinese biopharmaceutical company, has announced that it...
Inmagene Biopharmaceuticals Secures Exclusive License for HutchMed’s Drug Candidates IMG-007 and IMG-004
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that Sino-US biotech Inmagene Biopharmaceuticals has...
Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that the New Drug...
Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics
Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in...
China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with...
Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma
Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the...
Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels
Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the...
Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products
Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...
Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S....
Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients
Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...
Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development
Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan...
Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio...
Shanghai Junshi Biosciences’ Toripalimab Aims for Singapore Approval in Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...
Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the...
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...
Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...
Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology...